LYON, France, Dec. 12, 2016 (GLOBE NEWSWIRE) -- EDAP TMS S.A. (NASDAQ: EDAP ), the global leader in therapeutic ultrasound today announced that it has retained CG Capital, a leading capital markets development and research firm as their new investor relations counsel.
Marc Oczachowski, EDAP TMS Chief Executive Officer, commented, "CG Capital's expertise, contacts and strategic counsel in investor relations and in the healthcare sector will add significant value to our efforts to increase visibility within the financial and medical community. We look forward to leveraging their expertise as we continue to expand our activities bringing to U.S. patients our innovative therapeutic solutions."
"We will continue to develop EDAP TMS’ investor relations program," said Rich Cockrell, President of CG Capital. "I believe that EDAP TMS’ technology represents a compelling investment idea and we look forward to increasing the Company’s visibility through the introduction to new investors. I am confident that our firm will execute well on behalf of EDAP TMS’ shareholders."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters’ range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com , and http://www.hifu-planet.com .
About CG Capital
CG Capital is a capital markets development firm focused on enhancing investor awareness for small-to-midcap companies. It aligns a company's strategic goals to an institution's investment thesis and fundamentals to create a sound, long-term investment objective. The company also advises companies in various areas, including private and pre-IPO activity, mergers and acquisitions, bankruptcy, executive transitions, activist shareholders, hostile takeovers, downsizing, and event management. www.cg.capital .
Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company’s Annual Report on Form 20-F.
Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com CG CAPITAL 877.889.1972 investorrelations@cg.capital www.cg.capital
